Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia

International Journal of Hematology

Volumn 92, Issue 3, 2010, Pages 481-489

  Kikuchi, Misato ^a   Tanaka, Junji ^a   Kondo, Takeshi ^a   Hashino, Satoshi ^a   Kasai, Masaharu ^b   Kurosawa, Mitsutoshi ^c   Iwasaki, Hiroshi ^d   Morioka, Masanobu ^e   Kawamura, Tsugumichi ^f   Masauzi, Nobuo ^g   Fukuhara, Takashi ^h   Kakinoki, Yasutaka ⁱ   Kobayashi, Hajime ^j   Noto, Satoshi ^k   Asaka, Masahiro ^a   Imamura, Masahiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO HOKUYU HOSPITAL   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d Sapporo Kosei General Hospital   (Japan)

^e JAPANESE RED CROSS SOCIETY   (Japan)

^f HAKODATE CENTRAL GENERAL HOSPITAL   (Japan)

^g Hakodate City Hospital   (Japan)

^h ASAHIKAWA CITY HOSPITAL   (Japan)

ⁱ Asahikawa Kosei Hospital   (Japan)

^j Obihiro Kosei Hospital   (Japan)

^k KUSHIRO ROSAI HOSPITAL   (Japan)

more..

Author keywords

Adult ALL; Allogeneic transplantation; Flow cytometry; MRD; Polymerase chain reaction

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IMATINIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; STEROID; T LYMPHOCYTE RECEPTOR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT DISEASE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE REARRANGEMENT; HUMAN; LEUKEMIA RELAPSE; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 78549270049     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0670-1     Document Type: Article

References (22)

1. R Bassan O Spinelli E Oldani T Intermesoli M Tosi B Peruta, et al. 2009 Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood 113 4153 4162 1:CAS:528:DC%2BD1MXlvVGis7c%3D 10.1182/blood-2008-11- 185132 19141862
2. J Holowiecki M Krawczyk-Kulis S Giebel K Jagoda B Stella-Holowiecka B Piatkowska-Jakubas, et al. 2008 Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The polish adult leukemia group ALL 4-2002 MRD study Br J Haematol 142 227 237 10.1111/j.1365-2141.2008.07185.x 18492099 (Pubitemid 351994055)
3. M Brüggemann A Schrauder T Raff H Pfeifer M Dworzak OG Ottmann, et al. 2010 Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 Leukemia 24 521 535 10.1038/leu.2009.268 20033054
4. D Campana E Coustan-Smith 2004 Minimal residual disease studies by flow cytometry in acute leukemia Acta Haematol 112 8 15 10.1159/000077554 15178999 (Pubitemid 38716244)
5. T Toubai J Tanaka S Ota T Fukuhara S Hashino T Kondo, et al. 2005 Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients Am J Hematol 80 181 187 1:CAS:528:DC%2BD2MXht1Cgs7nO 10.1002/ajh.20461 16247752 (Pubitemid 41579539)
6. JS Chen E Coustan-Smith T Suzuki GA Neale K Mihara CH Pui, et al. 2001 Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia Blood 97 2115 2120 1:CAS:528:DC%2BD3MXjvFCqs7c%3D 10.1182/blood.V97.7.2115 11264179 (Pubitemid 32239094)
7. FY Mortuza M Papaioannou IM Moreira LA Coyle P Gameiro D Gandini, et al. 2002 Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia J Clin Oncol 20 1094 1104 10.1200/JCO.20.4.1094 11844835 (Pubitemid 34141855)
8. T Szczepański 2007 Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 21 622 626 17301806
9. M Brüggemann C Pott M Ritgen M Kneba 2004 Significance of minimal residual disease in lymphoid malignancies Acta Haematol 112 111 119 10.1159/000077566 15179011 (Pubitemid 38716256)
10. L Foroni AV Hoffbrand 2002 Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia Best Pract Res Clin Haematol 15 71 90 1:CAS:528:DC%2BD3sXjslSrur8%3D 10.1053/beha.2002.0186 11987917
11. T Szczepański MJ Willemse B Brinkhof ER van Wering M van der Burg JJ van Dongen 2002 Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease Blood 99 2315 2323 10.1182/blood.V99.7.2315 11895762 (Pubitemid 34525415)
12. J Brisco E Hughes SH Neoh PJ Sykes K Bradstock A Enno, et al. 1996 Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia Blood 87 5251 5256 1:CAS:528:DyaK28XjsFGitL4%3D 8652840
13. J Radich G Gehly A Lee R Avery E Bryant S Edmands, et al. 1997 Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation Blood 89 2602 2609 1:CAS:528: DyaK2sXitVyrsr0%3D 9116308 (Pubitemid 27143311)
14. G Kerst H Kreyenberg C Roth C Well K Dietz E Coustan-Smith, et al. 2005 Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR Br J Haematol 128 774 782 1:CAS:528:DC%2BD2MXjt1CltLo%3D 10.1111/j.1365-2141.2005.05401.x 15755280 (Pubitemid 40444869)
15. N Robillard H Cavé F Méchinaud C Guidal F Garnache-Ottou PS Rohrlich, et al. 2005 Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia Haematologica 90 1516 1523 1:CAS:528:DC%2BD2MXht12qtLrI 16266899
16. GA Neale E Coustan-Smith P Stow Q Pan X Chen CH Pui, et al. 2004 Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 18 934 938 1:CAS:528:DC%2BD2cXjtlyitLg%3D 10.1038/sj.leu.2403348 15029212 (Pubitemid 38714617)
17. J Sánchez J Serrano P Gómez F Martínez C Martín L Madero, et al. 2002 Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation Br J Haematol 116 686 694 10.1111/j.1365-2141.2002.3311a.x 11849234 (Pubitemid 34178675)
18. O Spinelli B Peruta M Tosi V Guerini A Salvi MC Zanotti, et al. 2007 Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia Haematologica 92 612 618 10.3324/haematol.10965 17488684 (Pubitemid 350144263)
19. B Patel L Rai G Buck SM Richards Y Mortuza W Mitchell, et al. 2010 Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 Br J Haematol 148 80 89 1:CAS:528:DC%2BC3cXhtFOkt78%3D 10.1111/j.1365-2141.2009.07941.x 19863538
20. D Campana 2009 Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia Hematol Oncol Clin N Am 23 1083 1098 10.1016/j.hoc.2009.07.010
21. I Thörn J Botling M Hermansson G Lönnerholm C Sundström R Rosenquist, et al. 2009 Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia Leuk Res 33 1047 1054 10.1016/j.leukres.2008.11.031 19157547
22. D Campana 2009 Minimal residual disease in acute lymphoblastic leukemia Semin Hematol 46 100 106 10.1053/j.seminhematol.2008.09.001 19100372